{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:29:32Z","timestamp":1790173772912,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:00:00Z","timestamp":1585094400000},"content-version":"vor","delay-in-days":329,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1093017"],"award-info":[{"award-number":["1093017"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1130423"],"award-info":[{"award-number":["1130423"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CLEARbridge Foundation"},{"name":"NHMRC Fellowships","award":["1104503"],"award-info":[{"award-number":["1104503"]}]},{"name":"NHMRC Fellowships","award":["1141295"],"award-info":[{"award-number":["1141295"]}]},{"name":"NHMRC Fellowships","award":["1119059"],"award-info":[{"award-number":["1119059"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1093\/annonc\/mdz075","type":"journal-article","created":{"date-parts":[[2019,3,10]],"date-time":"2019-03-10T04:10:57Z","timestamp":1552191057000},"page":"815-822","source":"Crossref","is-referenced-by-count":110,"title":["Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients"],"prefix":"10.1016","volume":"30","author":[{"given":"J.H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.P.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5092-5544","authenticated-orcid":false,"given":"S.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Spillane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.F.","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Stretch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Howle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.F.","family":"Kefford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1093\/annonc\/mdz075_bb0010","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"9687","key":"10.1093\/annonc\/mdz075_bb0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0140-6736(09)61397-0","article-title":"Cutaneous melanoma in the era of molecular profiling","volume":"374","author":"Thompson","year":"2009","journal-title":"Lancet"},{"issue":"19","key":"10.1093\/annonc\/mdz075_bb0020","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdz075_bb0025","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1093\/annonc\/mdz075_bb0030","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1093\/annonc\/mdz075_bb0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.ejca.2014.02.010","article-title":"Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy","volume":"50","author":"Khosrotehrani","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz075_bb0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/SLA.0b013e3181f9b8b6","article-title":"Lymph node ratio provides prognostic information in addition to American Joint Committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized","volume":"253","author":"Spillane","year":"2011","journal-title":"Ann Surg"},{"issue":"5","key":"10.1093\/annonc\/mdz075_bb0045","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1245\/s10434-016-5723-0","article-title":"Extranodal spread is associated with recurrence and poor survival in stage III cutaneous melanoma patients","volume":"24","author":"Crookes","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz075_bb0050","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2012.283","article-title":"BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma","volume":"133","author":"Mann","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1093\/annonc\/mdz075_bb0055","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.23794","article-title":"The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis","volume":"123","author":"Mocellin","year":"2008","journal-title":"Int J Cancer"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdz075_bb0060","doi-asserted-by":"crossref","first-page":"e21054","DOI":"10.1200\/JCO.2017.35.15_suppl.e21054","article-title":"The prognostic role of pre-operative serum lactate dehydrogenase (LDH) in patients with resected advanced melanoma","volume":"35","author":"Majithia","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz075_bb0065","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1158\/1078-0432.CCR-15-0321","article-title":"Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials","volume":"22","author":"Santiago-Walker","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1093\/annonc\/mdz075_bb0070","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz075_bb0075","doi-asserted-by":"crossref","first-page":"16723","DOI":"10.1038\/s41598-017-17079-6","article-title":"Cell-free DNA kinetics in a pre-clinical model of head and neck cancer","volume":"7","author":"Muhanna","year":"2017","journal-title":"Sci Rep"},{"key":"10.1093\/annonc\/mdz075_bb0080","doi-asserted-by":"crossref","first-page":"33.","DOI":"10.1186\/1471-2288-13-33","article-title":"External validation of a Cox prognostic model: principles and methods","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"10.1093\/annonc\/mdz075_bb0085","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"26","key":"10.1093\/annonc\/mdz075_bb0090","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","article-title":"Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma","volume":"31","author":"Ascierto","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz075_bb0095","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1093\/annonc\/mdz075_bb0100","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"2","key":"10.1093\/annonc\/mdz075_bb0105","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz075\/28492213\/mdz075.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/5\/815\/28770995\/mdz075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:57:09Z","timestamp":1624697829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419311640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0923753419311640"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz075","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}